Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 30;55(2):112-115.
doi: 10.5045/br.2020.2019191.

Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent

Hee Jin Lee  1 , Mi Jin Gu  2 , Eunjung Kong  3 , Jae Min Lee  1
Affiliations

Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent

Hee Jin Lee et al. Blood Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Histopathology of the thigh biopsy (A) low-power image (hematoxylin and eosin, ×100) and (B) high-power image (hematoxylin and eosin, ×400) showing medium to large cells with a cleaved nucleus and eosinophilic cytoplasm. (C) Tumor cells are diffusely positive for myeloperoxidase (immunohistochemical stain, ×400).
Fig. 2
Fig. 2
Initial thigh T2 magnetic resonance image (MRI) showing a 12×6×4 cm sized heterogeneous low signal intensity lesion in the proximal portion of the vastus lateralis muscle (A). Fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan showing high uptake of FDG in the right thigh and diffused uptake in the BM of the entire skeleton (B).
Fig. 3
Fig. 3
After 6 months of treatment, a significant reduction in tumor size was achieved (A). Barely noticeable tumor seen on the thigh T2 MRI scan. Significant reduction in the extent and intensity of FDG uptake seen on FDG-PET scan (B).
See this image and copyright information in PMC

Comment in

  • Myeloid sarcoma: "A cytological surprise".
    Jindal A, Kapatia G, Kaur M, Khera U, Shergill JS. Jindal A, et al. Diagn Cytopathol. 2022 Nov;50(11):538-539. doi: 10.1002/dc.25034. Epub 2022 Aug 12. Diagn Cytopathol. 2022. PMID: 35960136 No abstract available.

References

    1. Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016;40:1473–83. doi: 10.1097/PAS.0000000000000727. - DOI - PubMed
    1. Zhou T, Bloomquist MS, Ferguson LS, et al. Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis. Pediatr Hematol Oncol. 2020;37:76–89. doi: 10.1080/08880018.2019.1683107. - DOI - PubMed
    1. Pilieri SA, Orazi A, Falini B. Myeloid sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC Press; Lyon, France: 2008. pp. 140–1.
    1. Chen Z, Wang W, Rich A, Tang G, Hu S. Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: a report of 11 cases. Am J Hematol. 2015;90:E146–8. doi: 10.1002/ajh.24045. - DOI - PubMed
    1. Dasappa L, Thanky AH, Kuntegowdanahalli LC, et al. Myeloid sarcoma as the first sign of progression of chronic myeloid leukemia in medullary chronic phase: experience from a Tertiary Cancer Centre in Southern India. Gulf J Oncolog. 2017;1:21–5. - PubMed